Drug Trial Radar · NCT01616758
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
22
Actual
Start
Apr 2013
Primary completion
Jun 2014
Study completion Mar 2016
Sponsor
- Lead sponsor
- GTxIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification. Key secondary endpoints of objective response rate, progression free survival, time to progression, duration of response, effects on physical function, and effects on tumor progression in women with Androgen Receptor positive breast cancer will also be assessed.
Conditions
- Metastatic Breast Cancer
Interventions
GTx-024 9mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Treated With GTx024 With Clinical Benefit With AR Positive Breast CancerTime frame: 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
AMPM Research Clinic
Miami, Florida
Illinois Cancer Care, PC
Peoria, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Commonwealth Hematology-Oncology
Lawrence, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.